News headlines about Cellectis (NASDAQ:CLLS) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cellectis earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 45.5280409550833 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the media stories that may have impacted Accern’s scoring:
Shares of NASDAQ CLLS opened at $29.71 on Friday. Cellectis has a 1-year low of $21.25 and a 1-year high of $38.85. The stock has a market capitalization of $1,250.24, a PE ratio of -10.69 and a beta of 1.86.
Cellectis (NASDAQ:CLLS) last issued its quarterly earnings results on Monday, March 12th. The biotechnology company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.12). The business had revenue of $6.91 million during the quarter, compared to analysts’ expectations of $10.10 million. Cellectis had a negative net margin of 298.01% and a negative return on equity of 35.63%. research analysts expect that Cellectis will post -2.62 EPS for the current fiscal year.
Several brokerages have recently weighed in on CLLS. Nomura upped their target price on Cellectis to $73.00 and gave the stock a “buy” rating in a research report on Wednesday, March 14th. BidaskClub downgraded Cellectis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, January 16th. ValuEngine raised Cellectis from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Zacks Investment Research downgraded Cellectis from a “hold” rating to a “sell” rating in a research report on Wednesday, February 14th. Finally, Guggenheim began coverage on Cellectis in a research report on Friday, March 16th. They issued a “neutral” rating for the company. One analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $42.67.
COPYRIGHT VIOLATION WARNING: “Cellectis (CLLS) Receiving Somewhat Positive Media Coverage, Accern Reports” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/21/cellectis-clls-receiving-somewhat-positive-media-coverage-accern-reports.html.
Cellectis Company Profile
Cellectis SA, a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL).
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.